Marketing authorisation for AbbVie’s Aquipta
The therapy has been developed for the treatment of migraine among adults
Read More
Tag: approval
UCB announces approval of Bimzelx
The therapy is used to treat patients with psoriatic arthritis and axial spondyloarthritis
Read More
Approval provided for Angelini’s cenobamate
Treatment will now be used across Ireland among adults with focal onset seizures with epilepsy
Read More
Janssen reaches Akeega approval milestone
Treatment involves the treatment of adults with metastatic castration-resistant prostate cancer
Read More
SkinBioTherapeutics’ AxisBiotix-Ps gains approval
Company’s skin health product poised for vital European market launch following success in the UK
Read More
Stada and Xbrane receive approval for Ximluci
Biosimilar gains MHRA marketing authorisation for use throughout Britain
Read More
Celadon receives good manufacturing practice approval
MHRA approval relates to the company’s midlands-based drug development facilities
Read More
Regulatory approval received for Evgen’s SFX-01 study
New formulation may be suitable for large-scale trials and commercial supply in the future
Read More
Bavarian Nordic receives European approval of vaccine label Imvanex
Imvanex to include protection from monkeypox and diseases caused by vaccinia virus
Read More
Sanofi’s Xenpozyme approved by European Commission
Xenpozyme is a treatment for ASMD and the condition’s only current enzyme replacement therapy
Read More
Positive MHRA decision for Briviact
MHRA extends UCB’s therapy for the treatment of partial-onset seizures
Read More
Novartis Kymriah receives EC approval for lymphoma treatment
Approval for Kymriah follows a positive CHMP opinion and is applicable to all 27 EU member states
Read More
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
